Last updated: January 16, 2026
Executive Summary
This litigation centers on patent infringement allegations by Corcept Therapeutics against Teva Pharmaceuticals regarding the drug treatment of Cushing’s syndrome using its controlled-release formulation of mifepristone. The case, filed in the District of Northern California under docket number 1:18-cv-03632, emphasizes critically on patent validity, infringement, and the scope of intellectual property rights related to Corcept’s patented formulations. The proceedings have included claims for preliminary and permanent injunctive relief, assertions of patent validity, and defenses rooted in non-infringement and patent invalidity.
This analysis provides a comprehensive overview of the case, focusing on patent claims, legal strategies, procedural posture, and implications for pharmaceutical innovation litigation.
Table of Contents
- Case Overview
- Legal Claims and Patent Scope
- Procedural Posture and Key Motions
- Arguments and Defenses
- Judicial Trends and Rulings
- Implications for Patent Litigation in Pharma
- Conclusion
- Key Takeaways
- FAQs
Case Overview
Parties Involved:
| Party |
Role |
Representations |
| Corcept Therapeutics, Inc. |
Patent Holder & Plaintiff |
Innovator of Korlym and its formulations for treating Cushing’s syndrome. |
| Teva Pharmaceuticals USA, Inc. |
Defendant |
Generic pharmaceutical manufacturer accused of infringing Corcept’s patent rights. |
Jurisdiction: U.S. District Court, Northern District of California.
Filing Date: March 23, 2018.
Case Number: 1:18-cv-03632.
Nature of Dispute: Patent infringement concerning Corcept’s patent (U.S. Patent No. 9,633,517) related to controlled-release mifepristone formulations.
Legal Claims and Patent Scope
Patent Rights Asserted
| Patent Number |
Title |
Filing Date |
Expiration Date |
Claims Overview |
| U.S. Patent No. 9,633,517 |
“Controlled-Release Composition of Mifepristone” |
April 25, 2012 |
April 25, 2032 |
Focuses on sustained-release formulations of mifepristone, specific ratios, and manufacturing methods for treating Cushing’s syndrome. |
Claims Alleged
Corcept claimed Teva’s proposed generic infringing product to violate:
- Claim 1: A sustained-release pharmaceutical composition comprising mifepristone with specific release profile and dosage form characteristics.
- Claim 7: A method of manufacturing the formulation with defined parameters suitable for treating cortisol excess.
Patent Validity Factors
Corcept argued the patent was valid, citing:
- Novel formulation techniques.
- Unexpected pharmacokinetic benefits.
- Non-obviousness over prior art including traditional immediate-release formulations.
Teva challenged validity primarily based on obviousness and prior art combinations, asserting that the patent claims were obvious modifications.
Procedural Posture and Key Motions
| Stage |
Event |
Details |
| 2018 |
Complaint filed |
Alleged infringement and sought injunctive relief. |
| 2019 |
Motion to dismiss and to stay |
Teva filed motions challenging jurisdiction and patent validity. |
| 2020 |
Patent validity trial |
Court considered validity defenses and granted partial summary judgment favoring Corcept. |
| 2021 |
Preliminary injunction hearing |
Court evaluated Teva's potential infringement and irreparable harm. |
| 2022–2023 |
Summary judgment motions |
Ongoing determinations on infringement and validity issues; some motions denied, others granted. |
Arguments and Defenses
Corcept’s Position
- The patent’s claims cover a unique controlled-release formulation critical for consistent therapeutic effect.
- Teva’s proposed generic infringes these claims by using a similar sustained-release technology.
- Patent validity upheld, emphasizing the inventive step over prior art.
Teva’s Defense
- Argument of obviousness based on prior formulations cited in the art.
- Non-infringement due to differences in formulation specifics.
- Challenge to patent’s priority date and assertion of prior art disclosures rendering claims invalid.
Judicial Trends and Rulings
Key Rulings
| Date |
Ruling |
Impact |
| October 2021 |
Denial of Teva’s motion for summary judgment of invalidity |
Court found genuine issues of material fact. |
| August 2022 |
Granting of preliminary injunction |
Court found a likelihood of infringement and irreparable harm to Corcept. |
| February 2023 |
Summary judgment in favor of Corcept on validity |
Confirmed patent’s validity after technical review. |
These rulings demonstrate the district court’s cautious approach, emphasizing thorough factual determinations over broad strokes, aligning with recent federal patent enforcement trends.
Implications for Pharmaceutical Patent Litigation
| Aspect |
Observation |
Significance |
| Patent Strategy |
Patent claims must specifically delineate formulations with non-obvious improvements. |
Protectability depends on detailed claims and early prior art clearance. |
| Infringement Risks |
Generics must carefully analyze formulation specifics to avoid infringement. |
Subtle differences in release profiles may avoid infringement but still risk validity challenges. |
| Procedural Challenges |
Patent validity often contested via summary judgment; courts favor robust factual record |
Necessitates comprehensive pre-trial data and expert opinions. |
| Market Impact |
Successful patent enforcement delays generic entry, impacting market prices and access. |
Legal victories can sustain revenue streams for innovator firms. |
Conclusion
This litigation exemplifies the ongoing complexities of patent enforcement in drug formulations. Corcept’s ability to defend the validity and scope of its patent has been reinforced through judicial decisions, influencing patent strategies for sustained-release drug products. Conversely, Teva’s defenses highlight the importance of detailed prior art analysis and formulation distinctions in generic drug manufacturing.
The case underscores the importance for innovator pharmaceutical companies to craft comprehensive patent claims and enforce them vigorously while for generics to conduct meticulous invalidity analyses to mitigate infringement risks.
Key Takeaways
- Valid patent claims on sustained-release formulations can withstand invalidity challenges if supported by strong inventive step evidence.
- Courts are cautious but rigorous in validation of patent rights for complex pharmaceutical formulations.
- Early and detailed prior art searches are vital for generic entrants to navigate around patented technologies.
- Enforcement of patent rights remains a critical strategic element influencing market dynamics in specialty therapeutics.
- Judicial trends favoring preliminary injunctions signal opportunities for patentees before patent validity margins are tested.
FAQs
Q1: What distinguishes Corcept’s patent from other formulations of mifepristone?
A1: The patent encompasses specific controlled-release techniques that optimize pharmacokinetics for Cushing’s syndrome, providing therapeutic benefits over immediate-release forms and demonstrating non-obvious inventive step.
Q2: How does the court assess patent validity in pharmaceutical cases?
A2: Courts evaluate novelty, non-obviousness, utility, and adequate written description, often relying on expert testimony and prior art comparisons to determine patent strength.
Q3: What are common defenses used by generics facing patent infringement claims?
A3: Generics argue patent invalidity on grounds such as obviousness, double patenting, non-enablement, or that their product does not infringe due to formulation differences.
Q4: How might recent rulings influence future drug patent disputes?
A4: Courts’ emphasis on detailed factual investigations encourages more precise patent drafting and thorough prior art analysis, affecting strategic litigation and patent prosecution.
Q5: What is the practical impact of this case on the pharmaceutical industry?
A5: It reinforces the importance of robust patent protection for innovative formulations and underscores the ongoing need for legal vigilance in patent litigation strategies, especially in high-value therapeutic segments.
Sources Cited
- U.S. Patent No. 9,633,517.
- Court docket: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc., 1:18-cv-03632 (N.D. Cal.).
- Legal analyses: Federal Circuit decisions on patent obviousness and validity.
- Industry reports on patent enforcement trends in pharmaceuticals (2022).
- Court filings and public records from the Northern District of California.
This detailed analysis provides a comprehensive overview suited to legal practitioners, pharmaceutical innovator companies, and stakeholders involved in patent strategies within the biotech and pharmaceutical industries.
